


Thalidomide-O-PEG4-azide

Cat. No.:	HY-140844
CAS No.:	2380318-57-8
Molecular Formula:	C ₂₃ H ₂₉ N ₅ O ₉
Molecular Weight:	519.5
Target:	E3 Ligase Ligand-Linker Conjugates
Pathway:	PROTAC
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (481.23 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	1.9249 mL	9.6246 mL	19.2493 mL	
5 mM	0.3850 mL	1.9249 mL	3.8499 mL	
10 mM	0.1925 mL	0.9625 mL	1.9249 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Thalidomide-O-PEG4-azide is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. Thalidomide-O-PEG4-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

IC₅₀ & Target

Cereblon

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA